title: Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.
authors.affiliation: Department of Dermatology D40, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, 2400, Copenhagen, NV, Denmark. r.gniadecki@gmail.com.
authors.forename: R
authors.initials: R
authors.lastname: Gniadecki
authors.affiliation: Department of Dermatology D40, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, 2400, Copenhagen, NV, Denmark.
authors.forename: B
authors.initials: B
authors.lastname: Bang
authors.affiliation: Department of Dermatology D40, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, 2400, Copenhagen, NV, Denmark.
authors.forename: C
authors.initials: C
authors.lastname: Sand
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D000068582:Certolizumab Pegol / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D000068800:Etanercept / Q000627:therapeutic use; D005260:Female; D006801:Humans; D018664:Interleukin-12 / Q000276:immunology; D053759:Interleukin-23 / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D000069549:Ustekinumab / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D053759:Interleukin-23; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12; C529000:golimumab; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept; D000068582:Certolizumab Pegol